TARSUS PHARMACEUTICALS, INC. (TARS) Total liabilities 2020–2025
TARSUS PHARMACEUTICALS, INC. (TARS) total liabilities at each fiscal year-end, per SEC filings.
$218.7MFY2025 · since FY2020: $6.0M → $218.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $218.7M | +43.5% |
| FY2024 | $152.5M | +122.6% |
| FY2023 | $68.5M | +95.9% |
| FY2022 | $35.0M | +187.1% |
| FY2021 | $12.2M | +103.2% |
| FY2020 | $6.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More TARS financial trends
TARS RevenueTARS Net incomeTARS Net marginTARS Gross profitTARS Gross marginTARS Operating incomeTARS Operating marginTARS Operating cash flowTARS Free cash flowTARS Capital expendituresTARS Return on equityTARS Stock buybacksTARS Dividends paidTARS Total assetsTARS Shareholders’ equityTARS overview →